Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus TAVIST ALLERGY SINUS HEADACHE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ALLEGRA HIVES versus TAVIST ALLERGY SINUS HEADACHE.
CHILDREN'S ALLEGRA HIVES vs TAVIST ALLERGY/SINUS/HEADACHE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine-mediated effects, reducing pruritus and urticaria.
TAVIST ALLERGY/SINUS/HEADACHE contains clemastine fumarate (first-generation antihistamine) that competitively antagonizes histamine at H1 receptors, and acetaminophen that inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and fever; phenylpropanolamine is an alpha-adrenergic agonist that causes vasoconstriction of nasal mucosa.
Fexofenadine 180 mg orally once daily for adults and children 12 years and older.
1 tablet (acetaminophen 500 mg, diphenhydramine 12.5 mg, phenylephrine 10 mg) orally every 4-6 hours as needed; maximum 4 tablets per day
None Documented
None Documented
Terminal half-life: 14.4 hours; clinical context: supports twice-daily dosing in chronic urticaria
5-7 hours for clemastine; 12-15 hours for pseudoephedrine; acetaminophen half-life 2-3 hours. Context: Clemastine half-life supports twice-daily dosing; pseudoephedrine's longer half-life allows 6-8 hour dosing intervals
Fecal (80% as unchanged drug); renal (15%, mostly as metabolites; <5% unchanged)
Renal excretion of unchanged drug and metabolites accounts for 70-80%, with 15-25% fecal elimination; bilary excretion contributes to remaining
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination